Alastair P Greystoke

11PUBLICATIONS
121CO-AUTHORS
Cancer geneticsNanomedicineMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 01, 2025
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors.

Jia Liu, Anna R Minchom, Alastair Greystoke

|Jun 27, 2025
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial.

Susana Banerjee, Matthew G Krebs, Alastair Greystoke

|Sep 04, 2024
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors.

Babar Bashir, Judy S Wang, Gerald Falchook

|Aug 21, 2024
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.

Min Zhang, Aleksandra Bzura, Essa Y Baitei

|Jul 15, 2024
Sociodemographic Disparities in HER2+ Breast Cancer Trastuzumab Receipt: An English Population-Based Study.

Ruth P Norris, Rosie Dew, Alastair Greystoke

Pageof 2